North America Nifedipine Market

Market Overview

The North America Nifedipine market size is expected to reach a valuation of USD 661.21 million by 2030, growing at a CAGR of 8.95 % during the forecast period (2022–2030).

Nifedipine is a calcium channel blocker that stops calcium from passing through the walls of the arteries. High blood pressure, arrhythmias, and angina are all treated with nifedipine. Other therapeutic uses include ryanoids syndrome, cephalalgia, and so on. An increase in the senior population, healthcare spending, the incidence of chronic illnesses such as heart failure, arrhythmias, and hypertension, and healthcare awareness are all driving the market. Government regulations and negative pharmacological effects such as hypotension, stomach ulcers, and congestive heart failure, on the other hand, hinder market expansion. R&D operations are likely to yield new development opportunities. Other dihydropyridine calcium channel blockers, such as nitrendipine and nisoldipine, are used to address HBP disorders. Premature labour has been more common in recent years, causing a surge in demand for the aforementioned medications. Tocolytics are used to treat premature labour by preventing muscle contractions. Similarly, nifedipine protects preemies from health problems that arise as a result of their early delivery. Nifedipine market is valued at USD 856.66 million in 2020, and is predicted to reach USD 1,792.36 million by 2029, representing an 8.49% compound annual growth rate (CAGR).

The largest revenue share belongs to the North American nifedipine market, which is predicted to rise throughout the forecast period. The rise of chronic long-term illnesses as a significant health issue around the world is predicted to fuel growth. Furthermore, following COVID-19, the use of calcium channel blocking medicines such as Nicardipine, Norvasc, and Procardia has grown, resulting in an increase in acute and chronic health issues in the region.

Market Dynamics

Market Drivers

• Increase in Geriatric Population: Due to longer life expectancies and lower fertility rates, the old population is growing at a quicker rate. According to the United Nations, persons of age 65 and up outweigh children under the age of five in North America. As per the World Health Organization, the total global population of people of age 60 and above are expected to touch 2 billion by 2050, up from 900 million in 2015. There are a total of 200.4 million persons over the age of 65 in Europe and North America, and this increase in the geriatric population would increase the demand for Nifedipine in the market as they are more prone of getting ill as compared to younger generations.
• Increase in Chronic Heart Disease: The population of persons aged 65 and up is expanding, putting them at a higher risk of heart and vascular disease. According to HealthinAging.org, heart failure is the leading cause of hospitalisation in persons over 65. It further stated that at the age of 80, both men and women have a 20% lifetime risk of developing heart failure. Heart disease is growing more widespread not just among the elderly, but also among the younger population, and as a result, the demand for Nifedipine in the market is expected to increase in the North American region.

Market Restraints

• Associated Side Effects: The most prevalent adverse effects of nifedipine are cause for concern. Side effects of nifedipine include swelling of the extremities, dizziness, flushing, headache, heartburn, nausea, muscular cramps, mood swings, nervousness, cough, hives, itching, and constipation, among others. Concerns over the safety and tolerability of nifedipine medicine are projected to stymie market expansion in North America during the projection period.

 Market Opportunities

• Increasing Nifedipine Demand in Developing Countries to Attract Market Growth Opportunities: Factors such as an increase in the incidence and existence of target diseases such as cardiovascular disease, preterm labour, and Raynaud's syndrome, as well as a large patient population and expanding healthcare infrastructure are expected to propel market growth in emerging North American economies such as Mexico, Canada, and the United States. As a result, escalating efforts by key market participants and a growing elderly population base in developing nations at high risk of contracting target diseases will produce significant demand in the coming years in the North American region.

Regional Analysis

By 2030, the North America Nifedipine market is estimated to be worth USD 661.21 million, increasing at a CAGR of 8.95% over the forecast period (2022–2030). The North America market has the greatest revenue share, which is expected to grow during the projected period. Growth is expected to be drive by the emergence of chronic long-term illnesses as a major health issue around the world. Furthermore, as a result of COVID-19, the use of calcium channel blocking medications like Nicardipine, Norvasc, and Procardia has increased, resulting in a rise in acute and chronic health difficulties in the region.

Obesity also affects 332,915,000 adults in the United States, or 36.20%. People's unhealthy lifestyles put them at risk for diseases like high blood pressure, chest pains, and heart attacks, among others. As a result, overall drug consumption is rising, resulting in increased demand for Nifedipine. In 2021, the United States overtook every other country in terms of obesity rates. Because 36.20% of persons in the United States are overweight, calcium channel blockers are the most commonly prescribed drugs.

Ischemic heart disease was diagnosed in around 158,700 (6.1 per 1,000) Canadian individuals aged 20 and up. A total of 63,200 adults (2.3 per 1,000) experienced their first heart attack. In a given year, Canadian people with ischemic heart disease (IHD) were three times more likely than those without the illness to die of any cause. A total of 92,900 (5.2 per 1,000) Canadian adults aged 40 and up were diagnosed with heart failure for the first time and hence demand for Nifedipine in Canada is anticipated to accelerate during the forecast period.

Coronary heart disease has grown by 90% in Mexico since 1970. Heart disease was the second leading reason for death in recent years, with 59.7% of men and 47.9% of women dying from it. In Mexico, fatalities from heart disease accounted for more than 17% recently and this is the significant reason for the growth in demand for Nifedipine in the region.

Segmental Analysis

Nifedipine controlled-release tablets and nifedipine extended-action tablets are the two types of nifedipine pills. Nifedipine controlled-release tablets had the most market share in 2021. This significant increase can be ascribed to rising rates of hypertension and heart failure, the use of cutting-edge technology in pharmaceutical research, more funding from the government and international organisations, and increased public knowledge about the importance of preventative treatment.

The part is separated into primary pulmonary hypertension, heart failure, Raynaud's syndrome, cephalalgia, and others based on the application. In 2021, the most common cause of pulmonary hypertension was primary pulmonary hypertension. Obesity, poor dietary habits, excessive junk food intake, a lack of exercise, a rise in the younger generation's smoking and alcohol usage, and stress are all contributing factors. This category is expected to be driven by expanding government and private sector activities and firm programmes for the development of improved pharmaceuticals to treat hypertension and diabetes.

The North America nifedipine market is divided into hospital pharmacies, retail pharmacies, and other distribution channels. In 2020, the hospital pharmacies segment dominated the region’s market, and it is expected to rise at a faster CAGR throughout the forecast period.

Recent Developments

• Nifedipine soft gel capsules have been launched by The products were easily available in 10 and 20 mg potencies. Avet's comprehensive portfolio of generic oral solid goods now includes an AB-rated generic version to the calcium blocker medication Procardia.